Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Company research

Acrivon Therapeutics, Inc.

CIK 1781174Updated Nov 20, 2026

ACRV price & chart

Provider market data

Loading TradingView…

NASDAQ:ACRV on TradingView ↗

TradingView · Data may be delayed

About the company

Acrivon is a clinical stage biopharmaceutical company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 platform. The platform allows the company to interpret and quantify compound specific, drug-regulated pathway activity levels inside the intact cell in an unbiased manner, yielding terabytes of proprietary data and delivering rapid, actionable insights. The Generative Phosphoproteomics AP3 platform is comprised of a growing suite of powerful, internally-developed tools, including the AP3 Data Portal, converting multimodal data into structured data for generative AI analyses, the AP3 Kinase Substrate Relationship Predictor and the AP3 Interactome. These distinctive capabilities enable the company to go beyond the limitations of traditional drug discovery, as well as current AI-based target-centric drug discovery, and rapidly design highly differentiated compounds with desirable pathway effects through intracellular protein network analyses and advance these agents into the clinic for streamlined development.

8-K · 2026-01-08 · 0001193125-26-007007

Company description from the cited filing.

Financials

FY 2025 · USD
Revenue— · FY 2025
Net income-77,905,000USD · FY 2025
Source

10-K · 2026-03-19 · 0001193125-26-115123

2025-01-01 to 2025-12-31

Operating income-84,114,000USD · FY 2025
Source

10-K · 2026-03-19 · 0001193125-26-115123

2025-01-01 to 2025-12-31

Diluted EPS-2.02USD per share · FY 2025
Source

10-K · 2026-03-19 · 0001193125-26-115123

2025-01-01 to 2025-12-31

Some figures are unavailable for this reporting year.

balance sheet · annual statements
Line itemQ3 2025Q3 2024Q2 2026Q2 2025Q2 2024Q1 2026Q1 2025Q1 2024FY 2025FY 2024FY 2023FY 2022
ASSETS
AssetsUSD145,299,000
Source

10-Q · 2025-11-13 · 0001193125-25-280215

As of 2025-09-30

214,684,000
Source

10-Q · 2024-11-13 · 0000950170-24-125929

As of 2024-09-30

99,092,000
Source

10-Q · 2026-08-12 · 0001193125-26-346819

As of 2026-06-30

158,583,000
Source

10-Q · 2025-08-13 · 0000950170-25-108054

As of 2025-06-30

230,585,000
Source

10-Q · 2024-08-13 · 0000950170-24-095760

As of 2024-06-30

107,832,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

As of 2026-03-31

176,349,000
Source

10-Q · 2025-05-14 · 0000950170-25-071427

As of 2025-03-31

120,521,000
Source

10-Q · 2024-05-14 · 0000950170-24-059084

As of 2024-03-31

129,717,000
Source

10-K · 2026-03-19 · 0001193125-26-115123

As of 2025-12-31

196,588,000
Source

10-K · 2025-03-27 · 0000950170-25-046056

As of 2024-12-31

138,265,000
Source

10-K · 2024-03-28 · 0000950170-24-037618

As of 2023-12-31

181,226,000
Source

10-K · 2023-03-28 · 0000950170-23-010331

As of 2022-12-31

Property, Plant and Equipment, NetUSD5,189,000
Source

10-Q · 2025-11-13 · 0001193125-25-280215

As of 2025-09-30

4,670,000
Source

10-Q · 2024-11-13 · 0000950170-24-125929

As of 2024-09-30

4,248,000
Source

10-Q · 2026-08-12 · 0001193125-26-346819

As of 2026-06-30

5,072,000
Source

10-Q · 2025-08-13 · 0000950170-25-108054

As of 2025-06-30

3,467,000
Source

10-Q · 2024-08-13 · 0000950170-24-095760

As of 2024-06-30

4,653,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

As of 2026-03-31

4,676,000
Source

10-Q · 2025-05-14 · 0000950170-25-071427

As of 2025-03-31

3,408,000
Source

10-Q · 2024-05-14 · 0000950170-24-059084

As of 2024-03-31

4,889,000
Source

10-K · 2026-03-19 · 0001193125-26-115123

As of 2025-12-31

4,471,000
Source

10-K · 2025-03-27 · 0000950170-25-046056

As of 2024-12-31

3,479,000
Source

10-K · 2024-03-28 · 0000950170-24-037618

As of 2023-12-31

2,092,000
Source

10-K · 2023-03-28 · 0000950170-23-010331

As of 2022-12-31

Current assets:
Cash and Cash Equivalents, at Carrying ValueUSD35,405,000
Source

10-Q · 2025-11-13 · 0001193125-25-280215

As of 2025-09-30

43,415,000
Source

10-Q · 2025-11-13 · 0001193125-25-280215

As of 2024-09-30

41,417,000
Source

10-Q · 2026-08-12 · 0001193125-26-346819

As of 2026-06-30

41,895,000
Source

10-Q · 2026-08-12 · 0001193125-26-346819

As of 2025-06-30

46,006,000
Source

10-Q · 2025-08-13 · 0000950170-25-108054

As of 2024-06-30

34,064,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

As of 2026-03-31

39,154,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

As of 2025-03-31

24,607,000
Source

10-Q · 2025-05-14 · 0000950170-25-071427

As of 2024-03-31

41,499,000
Source

10-K · 2026-03-19 · 0001193125-26-115123

As of 2025-12-31

39,818,000
Source

10-K · 2025-03-27 · 0000950170-25-046056

As of 2024-12-31

36,015,000
Source

10-K · 2024-03-28 · 0000950170-24-037618

As of 2023-12-31

29,519,000
Source

10-K · 2023-03-28 · 0000950170-23-010331

As of 2022-12-31

Assets, CurrentUSD130,361,000
Source

10-Q · 2025-11-13 · 0001193125-25-280215

As of 2025-09-30

188,984,000
Source

10-Q · 2024-11-13 · 0000950170-24-125929

As of 2024-09-30

91,493,000
Source

10-Q · 2026-08-12 · 0001193125-26-346819

As of 2026-06-30

138,412,000
Source

10-Q · 2025-08-13 · 0000950170-25-108054

As of 2025-06-30

182,358,000
Source

10-Q · 2024-08-13 · 0000950170-24-095760

As of 2024-06-30

99,220,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

As of 2026-03-31

151,327,000
Source

10-Q · 2025-05-14 · 0000950170-25-071427

As of 2025-03-31

112,143,000
Source

10-Q · 2024-05-14 · 0000950170-24-059084

As of 2024-03-31

120,445,000
Source

10-K · 2026-03-19 · 0001193125-26-115123

As of 2025-12-31

181,629,000
Source

10-K · 2025-03-27 · 0000950170-25-046056

As of 2024-12-31

129,692,000
Source

10-K · 2024-03-28 · 0000950170-24-037618

As of 2023-12-31

132,095,000
Source

10-K · 2023-03-28 · 0000950170-23-010331

As of 2022-12-31

Prepaid Expense and Other Assets, CurrentUSD1,107,000
Source

10-Q · 2025-11-13 · 0001193125-25-280215

As of 2025-09-30

1,531,000
Source

10-Q · 2024-11-13 · 0000950170-24-125929

As of 2024-09-30

1,534,000
Source

10-Q · 2026-08-12 · 0001193125-26-346819

As of 2026-06-30

989,000
Source

10-Q · 2025-08-13 · 0000950170-25-108054

As of 2025-06-30

1,821,000
Source

10-Q · 2024-08-13 · 0000950170-24-095760

As of 2024-06-30

1,483,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

As of 2026-03-31

1,692,000
Source

10-Q · 2025-05-14 · 0000950170-25-071427

As of 2025-03-31

2,168,000
Source

10-Q · 2024-05-14 · 0000950170-24-059084

As of 2024-03-31

1,863,000
Source

10-K · 2026-03-19 · 0001193125-26-115123

As of 2025-12-31

2,149,000
Source

10-K · 2025-03-27 · 0000950170-25-046056

As of 2024-12-31

2,234,000
Source

10-K · 2024-03-28 · 0000950170-24-037618

As of 2023-12-31

4,344,000
Source

10-K · 2023-03-28 · 0000950170-23-010331

As of 2022-12-31

Operating Lease, Right-of-Use AssetUSD2,792,000
Source

10-Q · 2025-11-13 · 0001193125-25-280215

As of 2025-09-30

3,797,000
Source

10-Q · 2024-11-13 · 0000950170-24-125929

As of 2024-09-30

1,977,000
Source

10-Q · 2026-08-12 · 0001193125-26-346819

As of 2026-06-30

3,052,000
Source

10-Q · 2025-08-13 · 0000950170-25-108054

As of 2025-06-30

3,976,000
Source

10-Q · 2024-08-13 · 0000950170-24-095760

As of 2024-06-30

2,255,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

As of 2026-03-31

3,306,000
Source

10-Q · 2025-05-14 · 0000950170-25-071427

As of 2025-03-31

4,205,000
Source

10-Q · 2024-05-14 · 0000950170-24-059084

As of 2024-03-31

2,527,000
Source

10-K · 2026-03-19 · 0001193125-26-115123

As of 2025-12-31

3,554,000
Source

10-K · 2025-03-27 · 0000950170-25-046056

As of 2024-12-31

4,429,000
Source

10-K · 2024-03-28 · 0000950170-24-037618

As of 2023-12-31

4,770,000
Source

10-K · 2023-03-28 · 0000950170-23-010331

As of 2022-12-31

Other Assets, NoncurrentUSD1,647,000
Source

10-Q · 2025-11-13 · 0001193125-25-280215

As of 2025-09-30

1,179,000
Source

10-Q · 2024-11-13 · 0000950170-24-125929

As of 2024-09-30

1,179,000
Source

10-Q · 2026-08-12 · 0001193125-26-346819

As of 2026-06-30

1,647,000
Source

10-Q · 2025-08-13 · 0000950170-25-108054

As of 2025-06-30

—1,510,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

As of 2026-03-31

1,647,000
Source

10-Q · 2025-05-14 · 0000950170-25-071427

As of 2025-03-31

—1,653,000
Source

10-K · 2026-03-19 · 0001193125-26-115123

As of 2025-12-31

1,647,000
Source

10-K · 2025-03-27 · 0000950170-25-046056

As of 2024-12-31

——
LIABILITIES AND EQUITY
LiabilitiesUSD16,696,000
Source

10-Q · 2025-11-13 · 0001193125-25-280215

As of 2025-09-30

17,792,000
Source

10-Q · 2024-11-13 · 0000950170-24-125929

As of 2024-09-30

12,427,000
Source

10-Q · 2026-08-12 · 0001193125-26-346819

As of 2026-06-30

15,546,000
Source

10-Q · 2025-08-13 · 0000950170-25-108054

As of 2025-06-30

14,527,000
Source

10-Q · 2024-08-13 · 0000950170-24-095760

As of 2024-06-30

12,317,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

As of 2026-03-31

15,959,000
Source

10-Q · 2025-05-14 · 0000950170-25-071427

As of 2025-03-31

12,542,000
Source

10-Q · 2024-05-14 · 0000950170-24-059084

As of 2024-03-31

17,201,000
Source

10-K · 2026-03-19 · 0001193125-26-115123

As of 2025-12-31

19,802,000
Source

10-K · 2025-03-27 · 0000950170-25-046056

As of 2024-12-31

17,070,000
Source

10-K · 2024-03-28 · 0000950170-24-037618

As of 2023-12-31

10,751,000
Source

10-K · 2023-03-28 · 0000950170-23-010331

As of 2022-12-31

Stockholders’ equity:
Common Stock, Value, IssuedUSD31,000
Source

10-Q · 2025-11-13 · 0001193125-25-280215

As of 2025-09-30

31,000
Source

10-Q · 2024-11-13 · 0000950170-24-125929

As of 2024-09-30

42,000
Source

10-Q · 2026-08-12 · 0001193125-26-346819

As of 2026-06-30

31,000
Source

10-Q · 2025-08-13 · 0000950170-25-108054

As of 2025-06-30

31,000
Source

10-Q · 2024-08-13 · 0000950170-24-095760

As of 2024-06-30

38,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

As of 2026-03-31

31,000
Source

10-Q · 2025-05-14 · 0000950170-25-071427

As of 2025-03-31

23,000
Source

10-Q · 2024-05-14 · 0000950170-24-059084

As of 2024-03-31

31,000
Source

10-K · 2026-03-19 · 0001193125-26-115123

As of 2025-12-31

31,000
Source

10-K · 2025-03-27 · 0000950170-25-046056

As of 2024-12-31

23,000
Source

10-K · 2024-03-28 · 0000950170-24-037618

As of 2023-12-31

22,000
Source

10-K · 2023-03-28 · 0000950170-23-010331

As of 2022-12-31

Additional Paid in CapitalUSD384,356,000
Source

10-Q · 2025-11-13 · 0001193125-25-280215

As of 2025-09-30

370,224,000
Source

10-Q · 2024-11-13 · 0000950170-24-125929

As of 2024-09-30

398,543,000
Source

10-Q · 2026-08-12 · 0001193125-26-346819

As of 2026-06-30

380,562,000
Source

10-Q · 2025-08-13 · 0000950170-25-108054

As of 2025-06-30

367,750,000
Source

10-Q · 2024-08-13 · 0000950170-24-095760

As of 2024-06-30

389,396,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

As of 2026-03-31

376,732,000
Source

10-Q · 2025-05-14 · 0000950170-25-071427

As of 2025-03-31

240,932,000
Source

10-Q · 2024-05-14 · 0000950170-24-059084

As of 2024-03-31

387,255,000
Source

10-K · 2026-03-19 · 0001193125-26-115123

As of 2025-12-31

373,284,000
Source

10-K · 2025-03-27 · 0000950170-25-046056

As of 2024-12-31

237,675,000
Source

10-K · 2024-03-28 · 0000950170-24-037618

As of 2023-12-31

226,580,000
Source

10-K · 2023-03-28 · 0000950170-23-010331

As of 2022-12-31

Retained Earnings (Accumulated Deficit)USD-255,896,000
Source

10-Q · 2025-11-13 · 0001193125-25-280215

As of 2025-09-30

-174,145,000
Source

10-Q · 2024-11-13 · 0000950170-24-125929

As of 2024-09-30

-311,887,000
Source

10-Q · 2026-08-12 · 0001193125-26-346819

As of 2026-06-30

-237,662,000
Source

10-Q · 2025-08-13 · 0000950170-25-108054

As of 2025-06-30

-151,704,000
Source

10-Q · 2024-08-13 · 0000950170-24-095760

As of 2024-06-30

-293,923,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

As of 2026-03-31

-216,656,000
Source

10-Q · 2025-05-14 · 0000950170-25-071427

As of 2025-03-31

-132,906,000
Source

10-Q · 2024-05-14 · 0000950170-24-059084

As of 2024-03-31

-274,881,000
Source

10-K · 2026-03-19 · 0001193125-26-115123

As of 2025-12-31

-196,976,000
Source

10-K · 2025-03-27 · 0000950170-25-046056

As of 2024-12-31

-116,420,000
Source

10-K · 2024-03-28 · 0000950170-24-037618

As of 2023-12-31

-56,032,000
Source

10-K · 2023-03-28 · 0000950170-23-010331

As of 2022-12-31

Accumulated Other Comprehensive Income (Loss), Net of TaxUSD112,000
Source

10-Q · 2025-11-13 · 0001193125-25-280215

As of 2025-09-30

782,000
Source

10-Q · 2024-11-13 · 0000950170-24-125929

As of 2024-09-30

-33,000
Source

10-Q · 2026-08-12 · 0001193125-26-346819

As of 2026-06-30

106,000
Source

10-Q · 2025-08-13 · 0000950170-25-108054

As of 2025-06-30

-19,000
Source

10-Q · 2024-08-13 · 0000950170-24-095760

As of 2024-06-30

4,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

As of 2026-03-31

283,000
Source

10-Q · 2025-05-14 · 0000950170-25-071427

As of 2025-03-31

-70,000
Source

10-Q · 2024-05-14 · 0000950170-24-059084

As of 2024-03-31

111,000
Source

10-K · 2026-03-19 · 0001193125-26-115123

As of 2025-12-31

447,000
Source

10-K · 2025-03-27 · 0000950170-25-046056

As of 2024-12-31

-83,000
Source

10-K · 2024-03-28 · 0000950170-24-037618

As of 2023-12-31

-95,000
Source

10-K · 2023-03-28 · 0000950170-23-010331

As of 2022-12-31

Stockholders' Equity Attributable to ParentUSD128,603,000
Source

10-Q · 2025-11-13 · 0001193125-25-280215

As of 2025-09-30

196,892,000
Source

10-Q · 2025-11-13 · 0001193125-25-280215

As of 2024-09-30

86,665,000
Source

10-Q · 2026-08-12 · 0001193125-26-346819

As of 2026-06-30

143,037,000
Source

10-Q · 2026-08-12 · 0001193125-26-346819

As of 2025-06-30

216,058,000
Source

10-Q · 2025-08-13 · 0000950170-25-108054

As of 2024-06-30

95,515,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

As of 2026-03-31

160,390,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

As of 2025-03-31

107,979,000
Source

10-Q · 2025-05-14 · 0000950170-25-071427

As of 2024-03-31

112,516,000
Source

10-K · 2026-03-19 · 0001193125-26-115123

As of 2025-12-31

176,786,000
Source

10-K · 2025-03-27 · 0000950170-25-046056

As of 2024-12-31

121,195,000
Source

10-K · 2024-03-28 · 0000950170-24-037618

As of 2023-12-31

170,475,000
Source

10-K · 2023-03-28 · 0000950170-23-010331

As of 2022-12-31

Liabilities and EquityUSD145,299,000
Source

10-Q · 2025-11-13 · 0001193125-25-280215

As of 2025-09-30

214,684,000
Source

10-Q · 2024-11-13 · 0000950170-24-125929

As of 2024-09-30

99,092,000
Source

10-Q · 2026-08-12 · 0001193125-26-346819

As of 2026-06-30

158,583,000
Source

10-Q · 2025-08-13 · 0000950170-25-108054

As of 2025-06-30

230,585,000
Source

10-Q · 2024-08-13 · 0000950170-24-095760

As of 2024-06-30

107,832,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

As of 2026-03-31

176,349,000
Source

10-Q · 2025-05-14 · 0000950170-25-071427

As of 2025-03-31

120,521,000
Source

10-Q · 2024-05-14 · 0000950170-24-059084

As of 2024-03-31

129,717,000
Source

10-K · 2026-03-19 · 0001193125-26-115123

As of 2025-12-31

196,588,000
Source

10-K · 2025-03-27 · 0000950170-25-046056

As of 2024-12-31

138,265,000
Source

10-K · 2024-03-28 · 0000950170-24-037618

As of 2023-12-31

181,226,000
Source

10-K · 2023-03-28 · 0000950170-23-010331

As of 2022-12-31

Current liabilities:
Liabilities, CurrentUSD14,891,000
Source

10-Q · 2025-11-13 · 0001193125-25-280215

As of 2025-09-30

14,819,000
Source

10-Q · 2024-11-13 · 0000950170-24-125929

As of 2024-09-30

11,447,000
Source

10-Q · 2026-08-12 · 0001193125-26-346819

As of 2026-06-30

13,431,000
Source

10-Q · 2025-08-13 · 0000950170-25-108054

As of 2025-06-30

11,284,000
Source

10-Q · 2024-08-13 · 0000950170-24-095760

As of 2024-06-30

11,054,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

As of 2026-03-31

13,550,000
Source

10-Q · 2025-05-14 · 0000950170-25-071427

As of 2025-03-31

9,041,000
Source

10-Q · 2024-05-14 · 0000950170-24-059084

As of 2024-03-31

15,664,000
Source

10-K · 2026-03-19 · 0001193125-26-115123

As of 2025-12-31

17,214,000
Source

10-K · 2025-03-27 · 0000950170-25-046056

As of 2024-12-31

13,303,000
Source

10-K · 2024-03-28 · 0000950170-24-037618

As of 2023-12-31

6,516,000
Source

10-K · 2023-03-28 · 0000950170-23-010331

As of 2022-12-31

Operating Lease, Liability, CurrentUSD1,184,000
Source

10-Q · 2025-11-13 · 0001193125-25-280215

As of 2025-09-30

1,040,000
Source

10-Q · 2024-11-13 · 0000950170-24-125929

As of 2024-09-30

1,135,000
Source

10-Q · 2026-08-12 · 0001193125-26-346819

As of 2026-06-30

1,148,000
Source

10-Q · 2025-08-13 · 0000950170-25-108054

As of 2025-06-30

978,000
Source

10-Q · 2024-08-13 · 0000950170-24-095760

As of 2024-06-30

1,152,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

As of 2026-03-31

1,105,000
Source

10-Q · 2025-05-14 · 0000950170-25-071427

As of 2025-03-31

944,000
Source

10-Q · 2024-05-14 · 0000950170-24-059084

As of 2024-03-31

1,172,000
Source

10-K · 2026-03-19 · 0001193125-26-115123

As of 2025-12-31

1,057,000
Source

10-K · 2025-03-27 · 0000950170-25-046056

As of 2024-12-31

877,000
Source

10-K · 2024-03-28 · 0000950170-24-037618

As of 2023-12-31

726,000
Source

10-K · 2023-03-28 · 0000950170-23-010331

As of 2022-12-31

Accounts Payable, CurrentUSD996,000
Source

10-Q · 2025-11-13 · 0001193125-25-280215

As of 2025-09-30

1,506,000
Source

10-Q · 2024-11-13 · 0000950170-24-125929

As of 2024-09-30

861,000
Source

10-Q · 2026-08-12 · 0001193125-26-346819

As of 2026-06-30

1,163,000
Source

10-Q · 2025-08-13 · 0000950170-25-108054

As of 2025-06-30

1,261,000
Source

10-Q · 2024-08-13 · 0000950170-24-095760

As of 2024-06-30

1,162,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

As of 2026-03-31

3,691,000
Source

10-Q · 2025-05-14 · 0000950170-25-071427

As of 2025-03-31

2,056,000
Source

10-Q · 2024-05-14 · 0000950170-24-059084

As of 2024-03-31

2,277,000
Source

10-K · 2026-03-19 · 0001193125-26-115123

As of 2025-12-31

758,000
Source

10-K · 2025-03-27 · 0000950170-25-046056

As of 2024-12-31

5,048,000
Source

10-K · 2024-03-28 · 0000950170-24-037618

As of 2023-12-31

904,000
Source

10-K · 2023-03-28 · 0000950170-23-010331

As of 2022-12-31

Operating Lease, Liability, NoncurrentUSD1,805,000
Source

10-Q · 2025-11-13 · 0001193125-25-280215

As of 2025-09-30

2,973,000
Source

10-Q · 2024-11-13 · 0000950170-24-125929

As of 2024-09-30

980,000
Source

10-Q · 2026-08-12 · 0001193125-26-346819

As of 2026-06-30

2,115,000
Source

10-Q · 2025-08-13 · 0000950170-25-108054

As of 2025-06-30

3,243,000
Source

10-Q · 2024-08-13 · 0000950170-24-095760

As of 2024-06-30

1,263,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

As of 2026-03-31

2,409,000
Source

10-Q · 2025-05-14 · 0000950170-25-071427

As of 2025-03-31

3,501,000
Source

10-Q · 2024-05-14 · 0000950170-24-059084

As of 2024-03-31

1,537,000
Source

10-K · 2026-03-19 · 0001193125-26-115123

As of 2025-12-31

2,588,000
Source

10-K · 2025-03-27 · 0000950170-25-046056

As of 2024-12-31

3,767,000
Source

10-K · 2024-03-28 · 0000950170-24-037618

As of 2023-12-31

4,235,000
Source

10-K · 2023-03-28 · 0000950170-23-010331

As of 2022-12-31

Additional Financial Items
Deferred Tax Liabilities, NetUSD————————1,099,000
Source

10-K · 2026-03-19 · 0001193125-26-115123

As of 2025-12-31

1,272,000
Source

10-K · 2025-03-27 · 0000950170-25-046056

As of 2024-12-31

1,527,000
Source

10-K · 2024-03-28 · 0000950170-24-037618

As of 2023-12-31

1,785,000
Source

10-K · 2023-03-28 · 0000950170-23-010331

As of 2022-12-31

Short-term InvestmentsUSD93,849,000
Source

10-Q · 2025-11-13 · 0001193125-25-280215

As of 2025-09-30

144,038,000
Source

10-Q · 2024-11-13 · 0000950170-24-125929

As of 2024-09-30

48,542,000
Source

10-Q · 2026-08-12 · 0001193125-26-346819

As of 2026-06-30

95,528,000
Source

10-Q · 2025-08-13 · 0000950170-25-108054

As of 2025-06-30

134,531,000
Source

10-Q · 2024-08-13 · 0000950170-24-095760

As of 2024-06-30

63,673,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

As of 2026-03-31

110,481,000
Source

10-Q · 2025-05-14 · 0000950170-25-071427

As of 2025-03-31

85,368,000
Source

10-Q · 2024-05-14 · 0000950170-24-059084

As of 2024-03-31

77,083,000
Source

10-K · 2026-03-19 · 0001193125-26-115123

As of 2025-12-31

139,662,000
Source

10-K · 2025-03-27 · 0000950170-25-046056

As of 2024-12-31

91,443,000
Source

10-K · 2024-03-28 · 0000950170-24-037618

As of 2023-12-31

98,232,000
Source

10-K · 2023-03-28 · 0000950170-23-010331

As of 2022-12-31

Lines labelled “Derived” are calculated from reported figures.

cash flow · annual statements
Line itemQ4 2025Q4 2024Q3 2025Q3 2024Q2 2026Q2 2025Q1 2026Q1 2025FY 2025FY 2024FY 2023FY 2022
Cash flows from operating activities:
Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD——————-19,042,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2026-01-01 to 2026-03-31

-19,680,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2025-01-01 to 2025-03-31

-77,905,000
Source

10-K · 2026-03-19 · 0001193125-26-115123

2025-01-01 to 2025-12-31

-80,556,000
Source

10-K · 2025-03-27 · 0000950170-25-046056

2024-01-01 to 2024-12-31

-60,388,000
Source

10-K · 2024-03-28 · 0000950170-24-037618

2023-01-01 to 2023-12-31

-31,167,000
Source

10-K · 2023-03-28 · 0000950170-23-010331

2022-01-01 to 2022-12-31

Adjustments to reconcile net income to net cash provided by operating activities:
Share-based Payment Arrangement, Noncash ExpenseUSD——————2,181,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2026-01-01 to 2026-03-31

3,791,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2025-01-01 to 2025-03-31

14,720,000
Source

10-K · 2026-03-19 · 0001193125-26-115123

2025-01-01 to 2025-12-31

14,288,000
Source

10-K · 2025-03-27 · 0000950170-25-046056

2024-01-01 to 2024-12-31

11,618,000
Source

10-K · 2024-03-28 · 0000950170-24-037618

2023-01-01 to 2023-12-31

2,185,000
Source

10-K · 2023-03-28 · 0000950170-23-010331

2022-01-01 to 2022-12-31

Changes in operating assets and liabilities:
Increase (Decrease) in Accounts PayableUSD——————-1,202,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2026-01-01 to 2026-03-31

2,816,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2025-01-01 to 2025-03-31

1,536,000
Source

10-K · 2026-03-19 · 0001193125-26-115123

2025-01-01 to 2025-12-31

-3,586,000
Source

10-K · 2025-03-27 · 0000950170-25-046056

2024-01-01 to 2024-12-31

3,609,000
Source

10-K · 2024-03-28 · 0000950170-24-037618

2023-01-01 to 2023-12-31

-245,000
Source

10-K · 2023-03-28 · 0000950170-23-010331

2022-01-01 to 2022-12-31

Net Cash Provided by (Used in) Operating ActivitiesUSD——————-20,538,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2026-01-01 to 2026-03-31

-19,535,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2025-01-01 to 2025-03-31

-63,665,000
Source

10-K · 2026-03-19 · 0001193125-26-115123

2025-01-01 to 2025-12-31

-65,669,000
Source

10-K · 2025-03-27 · 0000950170-25-046056

2024-01-01 to 2024-12-31

-42,641,000
Source

10-K · 2024-03-28 · 0000950170-24-037618

2023-01-01 to 2023-12-31

-30,117,000
Source

10-K · 2023-03-28 · 0000950170-23-010331

2022-01-01 to 2022-12-31

Cash flows from investing activities:
Net Cash Provided by (Used in) Investing ActivitiesUSD——————13,127,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2026-01-01 to 2026-03-31

19,214,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2025-01-01 to 2025-03-31

66,100,000
Source

10-K · 2026-03-19 · 0001193125-26-115123

2025-01-01 to 2025-12-31

-51,771,000
Source

10-K · 2025-03-27 · 0000950170-25-046056

2024-01-01 to 2024-12-31

50,717,000
Source

10-K · 2024-03-28 · 0000950170-24-037618

2023-01-01 to 2023-12-31

-141,676,000
Source

10-K · 2023-03-28 · 0000950170-23-010331

2022-01-01 to 2022-12-31

Payments to Acquire Property, Plant, and EquipmentUSD——————14,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2026-01-01 to 2026-03-31

58,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2025-01-01 to 2025-03-31

1,669,000
Source

10-K · 2026-03-19 · 0001193125-26-115123

2025-01-01 to 2025-12-31

2,768,000
Source

10-K · 2025-03-27 · 0000950170-25-046056

2024-01-01 to 2024-12-31

1,288,000
Source

10-K · 2024-03-28 · 0000950170-24-037618

2023-01-01 to 2023-12-31

2,166,000
Source

10-K · 2023-03-28 · 0000950170-23-010331

2022-01-01 to 2022-12-31

Cash flows from financing activities:
Payment, Tax Withholding, Share-based Payment ArrangementUSD——————33,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2026-01-01 to 2026-03-31

344,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2025-01-01 to 2025-03-31

750,000
Source

10-K · 2026-03-19 · 0001193125-26-115123

2025-01-01 to 2025-12-31

2,520,000
Source

10-K · 2025-03-27 · 0000950170-25-046056

2024-01-01 to 2024-12-31

1,297,000
Source

10-K · 2024-03-28 · 0000950170-24-037618

2023-01-01 to 2023-12-31

—
Net Cash Provided by (Used in) Financing ActivitiesUSD——————-33,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2026-01-01 to 2026-03-31

-343,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2025-01-01 to 2025-03-31

-749,000
Source

10-K · 2026-03-19 · 0001193125-26-115123

2025-01-01 to 2025-12-31

121,027,000
Source

10-K · 2025-03-27 · 0000950170-25-046056

2024-01-01 to 2024-12-31

-1,554,000
Source

10-K · 2024-03-28 · 0000950170-24-037618

2023-01-01 to 2023-12-31

101,709,000
Source

10-K · 2023-03-28 · 0000950170-23-010331

2022-01-01 to 2022-12-31

Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD——————-7,444,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2026-01-01 to 2026-03-31

-664,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2025-01-01 to 2025-03-31

1,686,000
Source

10-K · 2026-03-19 · 0001193125-26-115123

2025-01-01 to 2025-12-31

3,587,000
Source

10-K · 2025-03-27 · 0000950170-25-046056

2024-01-01 to 2024-12-31

6,522,000
Source

10-K · 2024-03-28 · 0000950170-24-037618

2023-01-01 to 2023-12-31

-70,084,000
Source

10-K · 2023-03-28 · 0000950170-23-010331

2022-01-01 to 2022-12-31

Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD——35,607,000
Source

10-Q · 2025-11-13 · 0001193125-25-280215

As of 2025-09-30

43,611,000
Source

10-Q · 2025-11-13 · 0001193125-25-280215

As of 2024-09-30

41,612,000
Source

10-Q · 2026-08-12 · 0001193125-26-346819

As of 2026-06-30

42,096,000
Source

10-Q · 2026-08-12 · 0001193125-26-346819

As of 2025-06-30

34,258,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

As of 2026-03-31

39,352,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

As of 2025-03-31

41,702,000
Source

10-K · 2026-03-19 · 0001193125-26-115123

As of 2025-12-31

40,016,000
Source

10-K · 2025-03-27 · 0000950170-25-046056

As of 2024-12-31

36,429,000
Source

10-K · 2024-03-28 · 0000950170-24-037618

As of 2023-12-31

29,907,000
Source

10-K · 2023-03-28 · 0000950170-23-010331

As of 2022-12-31

Additional Financial Items
Share-based Payment Arrangement, ExpenseUSD——3,911,000
Source

10-Q · 2025-11-13 · 0001193125-25-280215

2025-07-01 to 2025-09-30

3,671,000
Source

10-Q · 2025-11-13 · 0001193125-25-280215

2024-07-01 to 2024-09-30

2,214,000
Source

10-Q · 2026-08-12 · 0001193125-26-346819

2026-04-01 to 2026-06-30

3,927,000
Source

10-Q · 2026-08-12 · 0001193125-26-346819

2025-04-01 to 2025-06-30

2,181,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2026-01-01 to 2026-03-31

3,791,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2025-01-01 to 2025-03-31

14,720,000
Source

10-K · 2026-03-19 · 0001193125-26-115123

2025-01-01 to 2025-12-31

14,288,000
Source

10-K · 2025-03-27 · 0000950170-25-046056

2024-01-01 to 2024-12-31

11,618,000
Source

10-K · 2024-03-28 · 0000950170-24-037618

2023-01-01 to 2023-12-31

2,185,000
Source

10-K · 2023-03-28 · 0000950170-23-010331

2022-01-01 to 2022-12-31

DepreciationUSD——300,000
Source

10-Q · 2025-11-13 · 0001193125-25-280215

2025-07-01 to 2025-09-30

300,000
Source

10-Q · 2025-11-13 · 0001193125-25-280215

2024-07-01 to 2024-09-30

400,000
Source

10-Q · 2026-08-12 · 0001193125-26-346819

2026-04-01 to 2026-06-30

300,000
Source

10-Q · 2026-08-12 · 0001193125-26-346819

2025-04-01 to 2025-06-30

383,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2026-01-01 to 2026-03-31

311,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2025-01-01 to 2025-03-31

1,356,000
Source

10-K · 2026-03-19 · 0001193125-26-115123

2025-01-01 to 2025-12-31

1,006,000
Source

10-K · 2025-03-27 · 0000950170-25-046056

2024-01-01 to 2024-12-31

536,000
Source

10-K · 2024-03-28 · 0000950170-24-037618

2023-01-01 to 2023-12-31

364,000
Source

10-K · 2023-03-28 · 0000950170-23-010331

2022-01-01 to 2022-12-31

Foreign Currency Transaction Gain (Loss), before TaxUSD————————200,000
Source

10-K · 2026-03-19 · 0001193125-26-115123

2025-01-01 to 2025-12-31

-100,000
Source

10-K · 2025-03-27 · 0000950170-25-046056

2024-01-01 to 2024-12-31

100,000
Source

10-K · 2024-03-28 · 0000950170-24-037618

2023-01-01 to 2023-12-31

—
General and Administrative ExpenseUSD——6,039,000
Source

10-Q · 2025-11-13 · 0001193125-25-280215

2025-07-01 to 2025-09-30

6,276,000
Source

10-Q · 2025-11-13 · 0001193125-25-280215

2024-07-01 to 2024-09-30

4,824,000
Source

10-Q · 2026-08-12 · 0001193125-26-346819

2026-04-01 to 2026-06-30

6,467,000
Source

10-Q · 2026-08-12 · 0001193125-26-346819

2025-04-01 to 2025-06-30

4,736,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2026-01-01 to 2026-03-31

6,248,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2025-01-01 to 2025-03-31

24,124,000
Source

10-K · 2026-03-19 · 0001193125-26-115123

2025-01-01 to 2025-12-31

25,207,000
Source

10-K · 2025-03-27 · 0000950170-25-046056

2024-01-01 to 2024-12-31

21,079,000
Source

10-K · 2024-03-28 · 0000950170-24-037618

2023-01-01 to 2023-12-31

—
Income Tax Expense (Benefit)USD————————0
Source

10-K · 2026-03-19 · 0001193125-26-115123

2025-01-01 to 2025-12-31

———
Investment Income, InterestUSD——————————7,000,000
Source

10-K · 2024-03-28 · 0000950170-24-037618

2023-01-01 to 2023-12-31

—
Net Income (Loss) Attributable to ParentUSD——-18,234,000
Source

10-Q · 2025-11-13 · 0001193125-25-280215

2025-07-01 to 2025-09-30

-22,441,000
Source

10-Q · 2025-11-13 · 0001193125-25-280215

2024-07-01 to 2024-09-30

-17,964,000
Source

10-Q · 2026-08-12 · 0001193125-26-346819

2026-04-01 to 2026-06-30

-21,006,000
Source

10-Q · 2026-08-12 · 0001193125-26-346819

2025-04-01 to 2025-06-30

-19,042,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2026-01-01 to 2026-03-31

-19,680,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2025-01-01 to 2025-03-31

-77,905,000
Source

10-K · 2026-03-19 · 0001193125-26-115123

2025-01-01 to 2025-12-31

-80,556,000
Source

10-K · 2025-03-27 · 0000950170-25-046056

2024-01-01 to 2024-12-31

-60,388,000
Source

10-K · 2024-03-28 · 0000950170-24-037618

2023-01-01 to 2023-12-31

-31,167,000
Source

10-K · 2023-03-28 · 0000950170-23-010331

2022-01-01 to 2022-12-31

Nonoperating Income (Expense)USD——1,453,000
Source

10-Q · 2025-11-13 · 0001193125-25-280215

2025-07-01 to 2025-09-30

2,699,000
Source

10-Q · 2025-11-13 · 0001193125-25-280215

2024-07-01 to 2024-09-30

704,000
Source

10-Q · 2026-08-12 · 0001193125-26-346819

2026-04-01 to 2026-06-30

1,643,000
Source

10-Q · 2026-08-12 · 0001193125-26-346819

2025-04-01 to 2025-06-30

860,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2026-01-01 to 2026-03-31

1,982,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2025-01-01 to 2025-03-31

6,209,000
Source

10-K · 2026-03-19 · 0001193125-26-115123

2025-01-01 to 2025-12-31

8,643,000
Source

10-K · 2025-03-27 · 0000950170-25-046056

2024-01-01 to 2024-12-31

—1,490,000
Source

10-K · 2023-03-28 · 0000950170-23-010331

2022-01-01 to 2022-12-31

Operating ExpensesUSD——19,687,000
Source

10-Q · 2025-11-13 · 0001193125-25-280215

2025-07-01 to 2025-09-30

25,140,000
Source

10-Q · 2025-11-13 · 0001193125-25-280215

2024-07-01 to 2024-09-30

18,668,000
Source

10-Q · 2026-08-12 · 0001193125-26-346819

2026-04-01 to 2026-06-30

22,649,000
Source

10-Q · 2026-08-12 · 0001193125-26-346819

2025-04-01 to 2025-06-30

19,902,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2026-01-01 to 2026-03-31

21,662,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2025-01-01 to 2025-03-31

84,114,000
Source

10-K · 2026-03-19 · 0001193125-26-115123

2025-01-01 to 2025-12-31

89,199,000
Source

10-K · 2025-03-27 · 0000950170-25-046056

2024-01-01 to 2024-12-31

67,103,000
Source

10-K · 2024-03-28 · 0000950170-24-037618

2023-01-01 to 2023-12-31

32,657,000
Source

10-K · 2023-03-28 · 0000950170-23-010331

2022-01-01 to 2022-12-31

Other Nonoperating Income (Expense)USD——-53,000
Source

10-Q · 2025-11-13 · 0001193125-25-280215

2025-07-01 to 2025-09-30

1,000
Source

10-Q · 2025-11-13 · 0001193125-25-280215

2024-07-01 to 2024-09-30

-156,000
Source

10-Q · 2026-08-12 · 0001193125-26-346819

2026-04-01 to 2026-06-30

-87,000
Source

10-Q · 2026-08-12 · 0001193125-26-346819

2025-04-01 to 2025-06-30

-129,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2026-01-01 to 2026-03-31

-14,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2025-01-01 to 2025-03-31

-270,000
Source

10-K · 2026-03-19 · 0001193125-26-115123

2025-01-01 to 2025-12-31

-558,000
Source

10-K · 2025-03-27 · 0000950170-25-046056

2024-01-01 to 2024-12-31

6,715,000
Source

10-K · 2024-03-28 · 0000950170-24-037618

2023-01-01 to 2023-12-31

1,490,000
Source

10-K · 2023-03-28 · 0000950170-23-010331

2022-01-01 to 2022-12-31

Proceeds from Stock Options ExercisedUSD———————1,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2025-01-01 to 2025-03-31

1,000
Source

10-K · 2026-03-19 · 0001193125-26-115123

2025-01-01 to 2025-12-31

90,000
Source

10-K · 2025-03-27 · 0000950170-25-046056

2024-01-01 to 2024-12-31

775,000
Source

10-K · 2024-03-28 · 0000950170-24-037618

2023-01-01 to 2023-12-31

24,000
Source

10-K · 2023-03-28 · 0000950170-23-010331

2022-01-01 to 2022-12-31

Unrealized Gain (Loss) on InvestmentsUSD——————————-100,000
Source

10-K · 2024-03-28 · 0000950170-24-037618

2023-01-01 to 2023-12-31

—

Lines labelled “Derived” are calculated from reported figures.

income statement · annual statements
Line itemQ4 2025Q4 2024Q3 2025Q3 2024Q2 2026Q2 2025Q1 2026Q1 2025FY 2025FY 2024FY 2023FY 2022
Operating Income (Loss)USD——-19,687,000
Source

10-Q · 2025-11-13 · 0001193125-25-280215

2025-07-01 to 2025-09-30

-25,140,000
Source

10-Q · 2025-11-13 · 0001193125-25-280215

2024-07-01 to 2024-09-30

-18,668,000
Source

10-Q · 2026-08-12 · 0001193125-26-346819

2026-04-01 to 2026-06-30

-22,649,000
Source

10-Q · 2026-08-12 · 0001193125-26-346819

2025-04-01 to 2025-06-30

-19,902,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2026-01-01 to 2026-03-31

-21,662,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2025-01-01 to 2025-03-31

-84,114,000
Source

10-K · 2026-03-19 · 0001193125-26-115123

2025-01-01 to 2025-12-31

-89,199,000
Source

10-K · 2025-03-27 · 0000950170-25-046056

2024-01-01 to 2024-12-31

-67,103,000
Source

10-K · 2024-03-28 · 0000950170-24-037618

2023-01-01 to 2023-12-31

-32,657,000
Source

10-K · 2023-03-28 · 0000950170-23-010331

2022-01-01 to 2022-12-31

Other Nonoperating Income (Expense)USD——-53,000
Source

10-Q · 2025-11-13 · 0001193125-25-280215

2025-07-01 to 2025-09-30

1,000
Source

10-Q · 2025-11-13 · 0001193125-25-280215

2024-07-01 to 2024-09-30

-156,000
Source

10-Q · 2026-08-12 · 0001193125-26-346819

2026-04-01 to 2026-06-30

-87,000
Source

10-Q · 2026-08-12 · 0001193125-26-346819

2025-04-01 to 2025-06-30

-129,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2026-01-01 to 2026-03-31

-14,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2025-01-01 to 2025-03-31

-270,000
Source

10-K · 2026-03-19 · 0001193125-26-115123

2025-01-01 to 2025-12-31

-558,000
Source

10-K · 2025-03-27 · 0000950170-25-046056

2024-01-01 to 2024-12-31

6,715,000
Source

10-K · 2024-03-28 · 0000950170-24-037618

2023-01-01 to 2023-12-31

1,490,000
Source

10-K · 2023-03-28 · 0000950170-23-010331

2022-01-01 to 2022-12-31

Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD————————-77,825,000
Source

10-K · 2026-03-19 · 0001193125-26-115123

2025-01-01 to 2025-12-31

———
Income Tax Expense (Benefit)USD————————0
Source

10-K · 2026-03-19 · 0001193125-26-115123

2025-01-01 to 2025-12-31

———
Net Income (Loss) Attributable to ParentUSD——-18,234,000
Source

10-Q · 2025-11-13 · 0001193125-25-280215

2025-07-01 to 2025-09-30

-22,441,000
Source

10-Q · 2025-11-13 · 0001193125-25-280215

2024-07-01 to 2024-09-30

-17,964,000
Source

10-Q · 2026-08-12 · 0001193125-26-346819

2026-04-01 to 2026-06-30

-21,006,000
Source

10-Q · 2026-08-12 · 0001193125-26-346819

2025-04-01 to 2025-06-30

-19,042,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2026-01-01 to 2026-03-31

-19,680,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2025-01-01 to 2025-03-31

-77,905,000
Source

10-K · 2026-03-19 · 0001193125-26-115123

2025-01-01 to 2025-12-31

-80,556,000
Source

10-K · 2025-03-27 · 0000950170-25-046056

2024-01-01 to 2024-12-31

-60,388,000
Source

10-K · 2024-03-28 · 0000950170-24-037618

2023-01-01 to 2023-12-31

-31,167,000
Source

10-K · 2023-03-28 · 0000950170-23-010331

2022-01-01 to 2022-12-31

Earnings Per Share, BasicUSD per share——-0.47
Source

10-Q · 2025-11-13 · 0001193125-25-280215

2025-07-01 to 2025-09-30

-0.59
Source

10-Q · 2025-11-13 · 0001193125-25-280215

2024-07-01 to 2024-09-30

-0.43
Source

10-Q · 2026-08-12 · 0001193125-26-346819

2026-04-01 to 2026-06-30

-0.55
Source

10-Q · 2026-08-12 · 0001193125-26-346819

2025-04-01 to 2025-06-30

-0.49
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2026-01-01 to 2026-03-31

-0.51
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2025-01-01 to 2025-03-31

-2.02
Source

10-K · 2026-03-19 · 0001193125-26-115123

2025-01-01 to 2025-12-31

-2.38
Source

10-K · 2025-03-27 · 0000950170-25-046056

2024-01-01 to 2024-12-31

-2.74
Source

10-K · 2024-03-28 · 0000950170-24-037618

2023-01-01 to 2023-12-31

-7.56
Source

10-K · 2023-03-28 · 0000950170-23-010331

2022-01-01 to 2022-12-31

Earnings Per Share, DilutedUSD per share——-0.47
Source

10-Q · 2025-11-13 · 0001193125-25-280215

2025-07-01 to 2025-09-30

-0.59
Source

10-Q · 2025-11-13 · 0001193125-25-280215

2024-07-01 to 2024-09-30

-0.43
Source

10-Q · 2026-08-12 · 0001193125-26-346819

2026-04-01 to 2026-06-30

-0.55
Source

10-Q · 2026-08-12 · 0001193125-26-346819

2025-04-01 to 2025-06-30

-0.49
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2026-01-01 to 2026-03-31

-0.51
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2025-01-01 to 2025-03-31

-2.02
Source

10-K · 2026-03-19 · 0001193125-26-115123

2025-01-01 to 2025-12-31

-2.38
Source

10-K · 2025-03-27 · 0000950170-25-046056

2024-01-01 to 2024-12-31

-2.74
Source

10-K · 2024-03-28 · 0000950170-24-037618

2023-01-01 to 2023-12-31

-7.56
Source

10-K · 2023-03-28 · 0000950170-23-010331

2022-01-01 to 2022-12-31

Weighted Average Number of Shares Outstanding, Basicshares——38,560,464
Source

10-Q · 2025-11-13 · 0001193125-25-280215

2025-07-01 to 2025-09-30

38,105,131
Source

10-Q · 2025-11-13 · 0001193125-25-280215

2024-07-01 to 2024-09-30

41,841,887
Source

10-Q · 2026-08-12 · 0001193125-26-346819

2026-04-01 to 2026-06-30

38,461,619
Source

10-Q · 2026-08-12 · 0001193125-26-346819

2025-04-01 to 2025-06-30

38,724,803
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2026-01-01 to 2026-03-31

38,350,444
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2025-01-01 to 2025-03-31

38,509,281
Source

10-K · 2026-03-19 · 0001193125-26-115123

2025-01-01 to 2025-12-31

33,791,817
Source

10-K · 2025-03-27 · 0000950170-25-046056

2024-01-01 to 2024-12-31

22,078,190
Source

10-K · 2024-03-28 · 0000950170-24-037618

2023-01-01 to 2023-12-31

4,121,912
Source

10-K · 2023-03-28 · 0000950170-23-010331

2022-01-01 to 2022-12-31

Weighted Average Number of Shares Outstanding, Dilutedshares——38,560,464
Source

10-Q · 2025-11-13 · 0001193125-25-280215

2025-07-01 to 2025-09-30

38,105,131
Source

10-Q · 2025-11-13 · 0001193125-25-280215

2024-07-01 to 2024-09-30

41,841,887
Source

10-Q · 2026-08-12 · 0001193125-26-346819

2026-04-01 to 2026-06-30

38,461,619
Source

10-Q · 2026-08-12 · 0001193125-26-346819

2025-04-01 to 2025-06-30

38,724,803
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2026-01-01 to 2026-03-31

38,350,444
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2025-01-01 to 2025-03-31

38,509,281
Source

10-K · 2026-03-19 · 0001193125-26-115123

2025-01-01 to 2025-12-31

33,791,817
Source

10-K · 2025-03-27 · 0000950170-25-046056

2024-01-01 to 2024-12-31

22,078,190
Source

10-K · 2024-03-28 · 0000950170-24-037618

2023-01-01 to 2023-12-31

4,121,912
Source

10-K · 2023-03-28 · 0000950170-23-010331

2022-01-01 to 2022-12-31

Additional Financial Items
Foreign Currency Transaction Gain (Loss), before TaxUSD————————200,000
Source

10-K · 2026-03-19 · 0001193125-26-115123

2025-01-01 to 2025-12-31

-100,000
Source

10-K · 2025-03-27 · 0000950170-25-046056

2024-01-01 to 2024-12-31

100,000
Source

10-K · 2024-03-28 · 0000950170-24-037618

2023-01-01 to 2023-12-31

—
General and Administrative ExpenseUSD——6,039,000
Source

10-Q · 2025-11-13 · 0001193125-25-280215

2025-07-01 to 2025-09-30

6,276,000
Source

10-Q · 2025-11-13 · 0001193125-25-280215

2024-07-01 to 2024-09-30

4,824,000
Source

10-Q · 2026-08-12 · 0001193125-26-346819

2026-04-01 to 2026-06-30

6,467,000
Source

10-Q · 2026-08-12 · 0001193125-26-346819

2025-04-01 to 2025-06-30

4,736,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2026-01-01 to 2026-03-31

6,248,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2025-01-01 to 2025-03-31

24,124,000
Source

10-K · 2026-03-19 · 0001193125-26-115123

2025-01-01 to 2025-12-31

25,207,000
Source

10-K · 2025-03-27 · 0000950170-25-046056

2024-01-01 to 2024-12-31

21,079,000
Source

10-K · 2024-03-28 · 0000950170-24-037618

2023-01-01 to 2023-12-31

—
Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD————————-78,014,000
Source

10-K · 2026-03-19 · 0001193125-26-115123

2025-01-01 to 2025-12-31

———
Interest Income (Expense), Nonoperating, NetUSD——1,506,000
Source

10-Q · 2025-11-13 · 0001193125-25-280215

2025-07-01 to 2025-09-30

2,698,000
Source

10-Q · 2025-11-13 · 0001193125-25-280215

2024-07-01 to 2024-09-30

860,000
Source

10-Q · 2026-08-12 · 0001193125-26-346819

2026-04-01 to 2026-06-30

1,730,000
Source

10-Q · 2026-08-12 · 0001193125-26-346819

2025-04-01 to 2025-06-30

989,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2026-01-01 to 2026-03-31

1,996,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2025-01-01 to 2025-03-31

6,479,000
Source

10-K · 2026-03-19 · 0001193125-26-115123

2025-01-01 to 2025-12-31

9,201,000
Source

10-K · 2025-03-27 · 0000950170-25-046056

2024-01-01 to 2024-12-31

——
Investment Income, InterestUSD——————————7,000,000
Source

10-K · 2024-03-28 · 0000950170-24-037618

2023-01-01 to 2023-12-31

—
Nonoperating Income (Expense)USD——1,453,000
Source

10-Q · 2025-11-13 · 0001193125-25-280215

2025-07-01 to 2025-09-30

2,699,000
Source

10-Q · 2025-11-13 · 0001193125-25-280215

2024-07-01 to 2024-09-30

704,000
Source

10-Q · 2026-08-12 · 0001193125-26-346819

2026-04-01 to 2026-06-30

1,643,000
Source

10-Q · 2026-08-12 · 0001193125-26-346819

2025-04-01 to 2025-06-30

860,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2026-01-01 to 2026-03-31

1,982,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2025-01-01 to 2025-03-31

6,209,000
Source

10-K · 2026-03-19 · 0001193125-26-115123

2025-01-01 to 2025-12-31

8,643,000
Source

10-K · 2025-03-27 · 0000950170-25-046056

2024-01-01 to 2024-12-31

—1,490,000
Source

10-K · 2023-03-28 · 0000950170-23-010331

2022-01-01 to 2022-12-31

Operating ExpensesUSD——19,687,000
Source

10-Q · 2025-11-13 · 0001193125-25-280215

2025-07-01 to 2025-09-30

25,140,000
Source

10-Q · 2025-11-13 · 0001193125-25-280215

2024-07-01 to 2024-09-30

18,668,000
Source

10-Q · 2026-08-12 · 0001193125-26-346819

2026-04-01 to 2026-06-30

22,649,000
Source

10-Q · 2026-08-12 · 0001193125-26-346819

2025-04-01 to 2025-06-30

19,902,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2026-01-01 to 2026-03-31

21,662,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2025-01-01 to 2025-03-31

84,114,000
Source

10-K · 2026-03-19 · 0001193125-26-115123

2025-01-01 to 2025-12-31

89,199,000
Source

10-K · 2025-03-27 · 0000950170-25-046056

2024-01-01 to 2024-12-31

67,103,000
Source

10-K · 2024-03-28 · 0000950170-24-037618

2023-01-01 to 2023-12-31

32,657,000
Source

10-K · 2023-03-28 · 0000950170-23-010331

2022-01-01 to 2022-12-31

Research and Development ExpenseUSD——13,648,000
Source

10-Q · 2025-11-13 · 0001193125-25-280215

2025-07-01 to 2025-09-30

18,864,000
Source

10-Q · 2025-11-13 · 0001193125-25-280215

2024-07-01 to 2024-09-30

13,844,000
Source

10-Q · 2026-08-12 · 0001193125-26-346819

2026-04-01 to 2026-06-30

16,182,000
Source

10-Q · 2026-08-12 · 0001193125-26-346819

2025-04-01 to 2025-06-30

15,166,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2026-01-01 to 2026-03-31

15,414,000
Source

10-Q · 2026-05-13 · 0001193125-26-221634

2025-01-01 to 2025-03-31

59,990,000
Source

10-K · 2026-03-19 · 0001193125-26-115123

2025-01-01 to 2025-12-31

63,992,000
Source

10-K · 2025-03-27 · 0000950170-25-046056

2024-01-01 to 2024-12-31

46,024,000
Source

10-K · 2024-03-28 · 0000950170-24-037618

2023-01-01 to 2023-12-31

—

Lines labelled “Derived” are calculated from reported figures.

Offerings

Registration 333-300095

S-3 · 2026-11-16 · 0001193125-26-463828

Terms from the governing filing for this registration; not a claim that the offering is open today.

Filing attachments

acrv-ex99_1.htm · 8-K · 2026-11-20

Safety, dose optimization, and early Phase 1/2 clinical results in AP3-predicted tumors for ACR-2316, a first-in-class WEE1/PKMYT1 inhibitor Timothy A. Yap1, Mohamad A. Salkeni2, Neel Gandhi3, Gerald Falchook4, David Sommerhalder5, Benedito A. Carneiro6, Judy Wang7, Monica Mita8, Kamlesh K. Sankhala9, Jeffery Russell10, David Levitz11, Lu Gan12, Besiana P. Beqo12, Kristina Masson12, Christina A. Scherer12, Erick Gamelin12, Eric Devroe12, Peter Blume-Jensen12, Mansoor R. Mirza12, Nicole Nevadunsk…

8-K · 2026-11-20 · 0001193125-26-470245

Read attachment ↗
d185923dex43.htm · S-3 · 2026-11-16

Exhibit 4.3 ACRIVON THERAPEUTICS, INC. INDENTURE Dated as of, 20 [ ] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. …

S-3 · 2026-11-16 · 0001193125-26-463828

Read attachment ↗
acrv-ex99_1.htm · 8-K · 2026-11-16

Exhibit 99.1 Acrivon Reports Third Quarter 2026 Financial Results and Business Highlights Immunology and inflammation (I&I) established as a second strategic pillar for company which is particularly well-suited for its AP3 precision medicine approach AI-driven AP3 platform was used for profiling against approved JAK inhibitors to identify recently acquired ACR-525, a Phase 2-ready, potentially best-in-class, highly selective JAK1 inhibitor, and a differentiated preclinical PKCθ program Late-…

8-K · 2026-11-16 · 0001193125-26-463444

Read attachment ↗
acrv-ex99_1.htm · 8-K · 2026-11-10

CORPORATE R&D AND KOL EVENT ACRIVON’S NEW I&I PROGRAMS DIFFERENTIATED ASSETS IDENTIFIED WITH PROPRIETARY AP3 PLATFORM NOVEMBER 10, 2026 Exhibit 99.1 Forward-looking statements Forward-looking statements Certain information contained in this presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future…

8-K · 2026-11-10 · 0001193125-26-455669

Read attachment ↗
acrv-ex99_1.htm · 8-K · 2026-11-06

Exhibit 99.1 Acrivon Expands into Immunology and Inflammation with Acquisition of Phase 2-Ready Differentiated, Oral JAK1 Inhibitor ACR-525, and PKCθ Inhibitor Preclinical Program from Aqilion AB Asset acquisition establishes immunology and inflammation (I&I) as a strategic pillar alongside oncology, extending the company into autoimmune disease As part of Acrivon’s due diligence, extensive AP3 profiling against approved JAK inhibitors and dupilumab revealed ACR-525 as a highly-selective, pot…

8-K · 2026-11-06 · 0001193125-26-450779

Read attachment ↗
acrv-ex99_1.htm · 8-K · 2026-08-12

EX-99.1 2 acrv-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts ACR-368 Phase 2b prespecified interim analysis and data from all-comer serous endometrial cancer (EC) treatment arms on track for second half of 2026 ACR-2316 Phase 1/2 trial in AP3-prioritized tumor types advancing in randomized dose expansion phase supported by a promising, favorable safety profile and durable single-agent cli…

8-K · 2026-08-12 · 0001193125-26-346859

Read attachment ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.